Business Description
CymaBay Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US23257D1037
Description
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.44 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.39 | |||||
| Debt-to-EBITDA | -1.34 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 12.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -3.4 | |||||
| 3-Year EPS without NRI Growth Rate | -10.2 | |||||
| 3-Year FCF Growth Rate | -1.9 | |||||
| 3-Year Book Growth Rate | 7.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.25 | |||||
| 9-Day RSI | 83.32 | |||||
| 14-Day RSI | 80.99 | |||||
| 6-1 Month Momentum % | 125.07 | |||||
| 12-1 Month Momentum % | 280.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.96 | |||||
| Quick Ratio | 10.96 | |||||
| Cash Ratio | 10.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.2 | |||||
| Shareholder Yield % | -9.48 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -327.23 | |||||
| Net Margin % | -339.11 | |||||
| FCF Margin % | -234.85 | |||||
| ROE % | -60.75 | |||||
| ROA % | -35.13 | |||||
| ROIC % | -423.81 | |||||
| ROC (Joel Greenblatt) % | -4969.24 | |||||
| ROCE % | -31.7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 106.84 | |||||
| PB Ratio | 12.65 | |||||
| Price-to-Tangible-Book | 12.64 | |||||
| EV-to-EBIT | -39.9 | |||||
| EV-to-Forward-EBIT | -19.01 | |||||
| EV-to-EBITDA | -40.22 | |||||
| EV-to-Forward-EBITDA | -19.04 | |||||
| EV-to-Revenue | 110.98 | |||||
| EV-to-Forward-Revenue | 1105.45 | |||||
| EV-to-FCF | -47.25 | |||||
| Price-to-Net-Current-Asset-Value | 14.12 | |||||
| Price-to-Net-Cash | 14.7 | |||||
| Earnings Yield (Greenblatt) % | -2.51 | |||||
| FCF Yield % | -1.96 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers